Form 4: Regeneron Director Michael S. Brown Executes Stock Option and Sells Shares Under 10b5-1 Plan

Regeneron Pharmaceuticals Director Michael S. Brown exercised stock options and sold shares of common stock on May 28, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On May 28, 2024, Michael S. Brown, a director of Regeneron Pharmaceuticals, exercised stock options to acquire 1,172 shares of common stock at a price of $625.60.
• Simultaneously, Brown sold 1,172 shares of Regeneron common stock at $974.86 per share.
• These transactions were executed under a pre-arranged trading plan intended to comply with Rule 10b5-1(c), which was adopted on February 26, 2024.
• Following these transactions, Brown directly owns 1,382 shares of Regeneron common stock.
• Brown also indirectly owns 5,000 shares through a trust for the benefit of his family and 6,162 shares through a SLAT.
• Brown has granted a power of attorney to several individuals to execute Forms 3, 4, and 5 on his behalf in accordance with Section 16(a) of the Securities Exchange Act of 1934.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document simply reports transactions by a company director under a pre-arranged trading plan, which is a common and expected practice.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

Directors and officers often use 10b5-1 plans to sell company stock over time to avoid accusations of insider trading. This is a common practice in the pharmaceutical industry and corporate governance.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a standard practice among corporate executives to manage their stock holdings while complying with insider trading regulations.
• Comparable companies like Amgen, Gilead Sciences, and Pfizer also see similar filings from their executives related to stock option exercises and sales under pre-arranged plans.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the use of a 10b5-1 plan suggests the impact is likely to be limited.

Key Dates